2011年11月-2012年1月的FDA的NDA医药股# Stock
K*g
1 楼
既然成为板斧了，那就为股版添点东西。
下面的医药股是2011年11-2012年1月的FDA的NDA待审批的。大家记住，任何药股的NDA
风险都比较大，要学会炒药股，切忌去赌药股的NDA.下面带星号的我觉得还可以值得研
究。
12/8/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision
on Anturol Gel for overactive bladder
12/7/2011 AFFYMAX INC AFFY Peginesatide (NDA) FDA panel to
review Peginesatide for anemia associated with chronic renal failure
***12/3/2011 Incyte Corporation INCY Ruxolitinib (NDA) FDA
decision on Ruxolitinib as a treatment for myelofibrosis
***12/01/2011 ONXX,
**12/01/2011 AMLN
11/27/2011 Transcept Pharmaceuticals, Inc. TSPT Intermezzo (NDA
resubmission) FDA to decide on Intermezzo as sleep aid for middle of the
night awakenings
***11/18/2011 Regeneron Pharmaceuticals REGN EYLEA (BLA) FDA
decision on EYLEA for treating neovascular age-related macular degeneration
(wet AMD)
**11/14/2011 biosante pharmaceuticals inc. BPAX Bio-T-Gel (NDA)
FDA decision on Bio-T-Gel for treatment of male hypogonadism or low
testosterone levels. 可能延期到明年2月。
**11/14/2011 Teva Pharmaceutical Industries Limited TEVA Bio-T-Gel
(NDA) FDA decision on Bio-T-Gel for treatment of male hypogonadism or low
testosterone levels。 可能延期到明年2月。
下面的医药股是2011年11-2012年1月的FDA的NDA待审批的。大家记住，任何药股的NDA
风险都比较大，要学会炒药股，切忌去赌药股的NDA.下面带星号的我觉得还可以值得研
究。
12/8/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision
on Anturol Gel for overactive bladder
12/7/2011 AFFYMAX INC AFFY Peginesatide (NDA) FDA panel to
review Peginesatide for anemia associated with chronic renal failure
***12/3/2011 Incyte Corporation INCY Ruxolitinib (NDA) FDA
decision on Ruxolitinib as a treatment for myelofibrosis
***12/01/2011 ONXX,
**12/01/2011 AMLN
11/27/2011 Transcept Pharmaceuticals, Inc. TSPT Intermezzo (NDA
resubmission) FDA to decide on Intermezzo as sleep aid for middle of the
night awakenings
***11/18/2011 Regeneron Pharmaceuticals REGN EYLEA (BLA) FDA
decision on EYLEA for treating neovascular age-related macular degeneration
(wet AMD)
**11/14/2011 biosante pharmaceuticals inc. BPAX Bio-T-Gel (NDA)
FDA decision on Bio-T-Gel for treatment of male hypogonadism or low
testosterone levels. 可能延期到明年2月。
**11/14/2011 Teva Pharmaceutical Industries Limited TEVA Bio-T-Gel
(NDA) FDA decision on Bio-T-Gel for treatment of male hypogonadism or low
testosterone levels。 可能延期到明年2月。
